[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560-1160", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1026472, "exercisedValue": 0, "unexercisedValue": 10583697}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 631042, "exercisedValue": 0, "unexercisedValue": 285755}, {"maxAge": 1, "name": "Dr. Mark  Smythe Ph.D.", "age": 59, "title": "Founder & VP Technology", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & Chief Technical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 37.62, "open": 36.95, "dayLow": 36.3, "dayHigh": 37.555, "regularMarketPreviousClose": 37.62, "regularMarketOpen": 36.95, "regularMarketDayLow": 36.3, "regularMarketDayHigh": 37.555, "beta": 2.163, "trailingPE": 13.361314, "forwardPE": -29.874739, "volume": 490474, "regularMarketVolume": 490474, "averageVolume": 671426, "averageVolume10days": 541090, "averageDailyVolume10Day": 541090, "bid": 36.5, "ask": 36.72, "bidSize": 100, "askSize": 100, "marketCap": 2181882880, "fiftyTwoWeekLow": 23.17, "fiftyTwoWeekHigh": 48.89, "priceToSalesTrailing12Months": 6.7384696, "fiftyDayAverage": 42.0908, "twoHundredDayAverage": 37.6799, "currency": "USD", "enterpriseValue": 1724062464, "profitMargins": 0.52765, "floatShares": 44378472, "sharesOutstanding": 59598000, "sharesShort": 3608116, "sharesShortPriorMonth": 3301009, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.060500003, "heldPercentInsiders": 0.01133, "heldPercentInstitutions": 1.0761, "shortRatio": 4.34, "shortPercentOfFloat": 0.0614, "impliedSharesOutstanding": 59598000, "bookValue": 8.936, "priceToBook": 4.0969114, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": 170848992, "trailingEps": 2.74, "forwardEps": -1.43, "enterpriseToRevenue": 5.325, "enterpriseToEbitda": 11.489, "52WeekChange": 0.4863987, "SandP52WeekChange": 0.22263205, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PTGX", "underlyingSymbol": "PTGX", "shortName": "Protagonist Therapeutics, Inc.", "longName": "Protagonist Therapeutics, Inc.", "firstTradeDateEpochUtc": 1470922200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "db1f1c69-f5b8-3245-b848-39f5038697fa", "messageBoardId": "finmb_129263324", "gmtOffSetMilliseconds": -18000000, "currentPrice": 36.61, "targetHighPrice": 67.0, "targetLowPrice": 47.0, "targetMeanPrice": 57.5, "targetMedianPrice": 58.0, "recommendationKey": "none", "numberOfAnalystOpinions": 10, "totalCash": 468720992, "totalCashPerShare": 7.865, "ebitda": 150068000, "totalDebt": 10900000, "quickRatio": 10.574, "currentRatio": 10.695, "totalRevenue": 323795008, "debtToEquity": 2.049, "revenuePerShare": 5.3, "returnOnAssets": 0.19959, "returnOnEquity": 0.40967998, "freeCashflow": 144935008, "operatingCashflow": 230290000, "grossMargins": 1.0, "ebitdaMargins": 0.46347, "operatingMargins": -8.86695, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]